Alberto Carmona Bayonas

Publications

• C0396: Thrombophilia in Thrombosis and Cancer
• Causal Considerations Can Inform the Interpretation of Surprising Associations in Medical Registries
• Medicine before and after David Cox
• Olaratumab-induced Biomarker Modulation in Sarcomas—Letter
• SUNRISE-DI study. The daily sunrise is easier to predict than the benefit of adjuvant treatment in colon cancer
• Decoding risk: Caravaggio's insights into risk factors for anticoagulation in cancer-associated thrombosis
• Neutropenia febril: análisis de los factores pronósticos y el tratamiento adaptado al riesgo. Revisión crítica
• Estoicismo frente al cáncer: riesgo o protección
• Health related quality of life and utility weights of medical oncology inpatients
• Role of Chemotherapy in Advanced Gastric Cancer: Review from a Latin American Perspective
• Bayesian interpretation of immunotherapy trials with dynamic treatment effects
• Learning in times of stress: Lessons from COVID-19 that will last throughout this century
• Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit
• Predictors of Anxiety, Depression, and Somatization: A Prospective Study of 1807 Cancer Patients Short title
• Geriatric assessment predicts survival and competing mortality in colorectal cancer elderly patients. Can it help in adjuvant therapy decision?
• A Delphi Study on the Management of Neuropathic Cancer Pain in Spain: The DOLNEO Study
• Clinicians’ and Advanced Cancer Patients’ Estimates of Treatment Efficacy and Toxicity in Oncologic Treatment
• Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial
• Comparativa entre ramucirumab-paclitaxel y quimioterapia convencional como tratamiento de segunda línea para el adenocarcinoma gástrico avanzado en un registro nacional
• Anxiety and depression in patients with advanced cancer during the COVID-19 pandemic
• State of the scientific evidence and recommendations for the management of older patients with gastric cancer
• Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients
• Stoic attitude in patients with cancer from the NEOcoping study: Cross-sectional study
• A prognostic model to identify short survival expectancy of medical oncology patients at the time of hospital discharge
• Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial
• Can Oncologists Prompt Patient Prognostic Awareness to Enhance Decision-Making? Data From the NEOetic Study
• Prediction of the generalization of myasthenia gravis with purely ocular symptoms at onset: a multivariable model development and validation
• CO039 - REGISTRO SEPTRALU: DATOS DE VIDA REAL DE 522 PACIENTES CON UN TUMOR NEUROENDOCRINO AVANZADO TRATADOS CON 177LU-DOTATATE
• Resilience, Social Support, and Anxious Preoccupation in Patients with Advanced Cancer during COVID-19 Pandemic
• P-30 First-line (1L) treatment patterns in advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma (GC/GEJC/EAC): Data from the Spanish AGAMENON-SEOM registry
• Sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid carcinoma: The phase 2 SETHY, GETNE-T2318 trial.
• Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence
• Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer
• Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin
• 1940TiP Sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid carcinoma and anaplastic thyroid carcinoma: The phase II SETHY, GETNE-T2318 trial design
• Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
• 1645O Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial
• 605P First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
• 723O Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multi-cohort basket phase II trial (CABATEN/GETNE-T1914)
• Cabozantinib plus atezolizumab in locally advanced/metastatic adrenocortical carcinoma: Results from a multi-cohort basket phase II trial, CABATEN/GETNE-T1914.
• Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells
• Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
• Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study
• Prospective study of the real impact of fusion centered genomic assays in patient management in a national collaborative group: the GETHI-XX-16 study
• Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding.
• Physical Activity in Patients with Advanced Cancer: Sociodemographic, Clinical, and Psychological Correlates
• Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry.
• Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
• Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry.
• SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022).
• Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study.
• Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study.
• The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy.
• Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry.
• Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial.
• Prediction of serious complications in patients with cancer and pulmonary thromboembolism: validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO Study
• Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy.
• Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry
• Physical Activity in Patients with Advanced Cancer: Sociodemographic, Clinical, and Psychological Correlates
• Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients
• Anti-Tumor Functions of Prelatent Antithrombin on Glioblastoma Multiforme Cells
• Erratum to “Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings” [Eur J Cancer 136 (September 2020) 159−168]
• Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study
• Prospective Study Comparing Clinicians’ and Cancer Patients’ Estimates of Risk of Relapse and Toxicity with Adjuvant Chemotherapy
• Psychometric Properties of the PDRQ-9 in Cancer Patients: Patient-Doctor Relationship Questionnaire
• Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy
• Impact of Obesity on Quality of Life, Psychological Distress, and Coping on Patients with Colon Cancer
• Abstract PS6-45: Prognostic significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with breast cancer receivingneoadjuvant chemotherapy
• Durvalumab plus tremelimumab for the treatment of patients (pts) with refractory and progressive advanced thyroid carcinoma: A phase II multicohort trial (DUTHY / GETNE T1812)
• 1410P Gastric cancer: Data from the AGAMENON-SEOM study
• Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
• Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data
• Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ROS study.
• PO-61 Venous thromboembolic disease in cancer patients treated with immunotherapy: analysis of the TESEO study
• 1394P Frequentist and Bayesian analysis of second line treatment effectiveness in AGAMENON-SEOM gastric cancer registry
• 575TiP Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)
• SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus
• P-168 Differences in coping strategies used by colorectal vs. non-colorectal cancer patients: Data from the Neoetic-SEOM study
• 1107P Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601)
• External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.
• Social support, coping strategies and sociodemographic factors in women with breast cancer.
• Bayesian interpretation of the ESMO guideline for localized colorectal cancer: a better IDEA.
• External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
• Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
• External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
• Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus.
• Coping strategies and depressive symptoms in cancer patients
• Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
• Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings
• Effects of pessimism, depression, fatigue, and pain on functional health-related quality of life in patients with resected non-advanced breast cancer
• Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry
• Incidence of sleep problems and their mediating role on depression and anxious preoccupation in patients with resected, non-advanced cancer: data from NEOcoping study
• Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer
• Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology)
• Differences in coping strategies among young adults and the elderly with cancer
• A snapshot of cancer-associated thromboembolic disease in 2018–2019: First data from the TESEO prospective registry
• Kidney transplantation from donors after uncontrolled circulatory death: the Spanish experience
• Does active smoking worsen Covid-19?
• Emotional functioning to screen for psychological distress in breast and colorectal cancer patients prior to adjuvant treatment initiation
• TESEO, cancer-associated thrombosis registry from the Spanish Society of Medical Oncology (SEOM)
• Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in patients with colon cancer: a latent class analysis
• Biopsychosocial and clinical characteristics in patients with resected breast and colon cancer at the beginning and end of adjuvant treatment
• Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
• A Trial of Lopinavir-Ritonavir in Covid-19
• Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)
• SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)
• Common misconceptions in the prognostic evaluation of clinically stable patients with febrile neutropenia and solid tumors
• Intensive care in cancer patients in the age of immunotherapy and molecular therapies: Commitment of the SEOM-SEMICYUC
• 4CPS-123 Role of docetaxel in combination with cisplatin and capecitabine in advanced gastric cancer
• Complexity and uncertainty in the critical care of cancer patients in the era of immunotherapy and targeted therapies
• CP-117 Use and effectiveness of firstline chemotherapy regimens in advanced gastric cancer: evolution from 2009 to 2016
• Outpatient management of cancer-associated pulmonary embolism (PE): analysis of lung carcinoma (LC) cohort from the Epiphany study
• Cognitive functions, coping strategies and psychological distress in patients with resected non-advanced cancer receiving chemotherapy: NEOcoping study data
• Treatment of advanced gastric cancer based on Lauren’s histological: Real-world data from the AGAMEMON National Cancer Registry
• Why Young Patients with Cancer Require Different Coping Tools?
• First-line triplet or doublet chemotherapy for advanced gastric cancer: Analysis of 970 patients from a community practice registry
• Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in advanced gastric cancer: AGAMENON study data
• 4CPS-122 Efficacy of different chemotherapy regimens associated with trastuzumab in her2-positive advanced gastric cancer: data from the national register agamenon
• 4CPS-123 Role of docetaxel in combination with cisplatin and capecitabine in advanced gastric cancer
• Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial
• Key points to optimizing management and research on cancer-associated thrombosis
• The prognostic impact of additional intrathoracic findings in patients with cancer-related pulmonary embolism
• Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry
• Psychometric properties of liverpool stoicism scale (LSS) in a cohort of patients with resected cancer in adjuvant treatment,Propiedades psicométricas de la liverpool stoicism scale (LSS) en una cohorte de pacientes con cáncer resecado en tratamiento adyuvante
• Systemic treatment of metastatic disease,Tratamiento sistémico de la enfermedad metastásica
• Breathlessness in advanced cancer patients: Protocols and recommendations
• Factors Predicting Adherence to a Tailored-Dose Adjuvant Treatment on the Basis of Geriatric Assessment in Elderly People With Colorectal Cancer: A Prospective Study
• SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018)
• Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study
• Top ten errors of statistical analysis in observational studies for cancer research
• Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
• Intensive care in cancer patients in the age of immunotherapy and molecular therapies: Commitment of the SEOM-SEMICYUC,Cuidados intensivos en pacientes con cáncer en la era de la inmunoterapia y las terapias moleculares: el compromiso de la SEOM-SEMICYUC
• Quality of life, coping, and psychological and physical symptoms after surgery for non-metastatic digestive tract cancer
• Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis
• Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
• Psychometric properties of the Shared Decision-Making Questionnaire (SDM-Q-9) in oncology practice,Propiedades psicométricas del Questionnaire Shared Decision-Making (SDM-Q-9) en oncología
• Geriatric assessment predicts survival and competingmortality in elderly patients with early colorectal cancer: Can it help in adjuvant therapy decision-making?
• Complexity and uncertainty in the critical care of cancer patients in the era of immunotherapy and targeted therapies,Complejidad e incertidumbre en cuidados críticos para pacientes con cáncer en la era de la inmunoterapia y terapias dirigidas
• Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: The Getne-Trasgu study
• Chilean Gastric Cancer Task Force A study protocol to obtain a clinical and molecular classification of a cohort of gastric cancer patients
• Optimizing somatostatin analog use in well or moderately differentiated gastroenteropancreatic neuroendocrine tumors
• Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: Real-world data from the AGAMENON National Cancer Registry
• Psychometric properties and factorial analysis of invariance of the Satisfaction with Life Scale (SWLS) in cancer patients
• Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis
• Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status
• CISNE or MASCC, which predictor is really the weakest in febrile neutropenia?
• Prospective analysis of psychological differences between adult and elderly cancer patients during postoperative adjuvant chemotherapy
• Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain
• Comparison of Coping, Psychological Distress, and Level of Functioning in Patients With Gastric and Colorectal Cancer Before Adjuvant Chemotherapy
• The mediating role of spirituality (meaning, peace, faith) between psychological distress and mental adjustment in cancer patients
• Factors associated with anxiety and depression in cancer patients prior to initiating adjuvant therapy
• Risk of malnutrition and emotional distress as factors affecting health-related quality of life in patients with resected cancer
• The relationship between physician and cancer patient when initiating adjuvant treatment and its association with sociodemographic and clinical variables
• Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry
• Management of Infection and Febrile Neutropenia in Patients with Solid Cancer,Manejo de la infección y la neutropenia febril en el paciente con cáncer sólido
• Prognostic Assessment of Febrile Neutropenia in the Emergency Department
• Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
• Implication of Hepsin from primary tumor in the prognosis of colorectal cancer patients
• A Prognostic Model of Survival After First Hospital Discharge of Cancer Patients
• CP-152 Applying the results from the toga trial into clinical practice: Data from the agamenon multicentre study
• Venous Thromboembolism in Cancer Patients: Comparison of Lung Cancer Patients to Other Solid Tumor Patients in a Prospective Observational Study
• CP-165 Efficacy and toxicity of combined chemotherapy with platinum and fluoropyrimidine in gastric cancer: Agamenon study cohort
• C0269: Outpatient Management of Cancer-Related Pulmonary Embolism: Analysis of 562 Consecutive Patients from the Epiphany Study
• Assessment of psychological distress, coping, and spirituality in patients with resected, non-metastatic vs unresectable advanced cancer. Data from the NEOcoping and NEOetic_SEOM studies
• Change in quality of life and psychological distress in patients with resected non-metastatic vs unresectable advanced cancer undergoing systemic treatment
• Outpatient management of cancer-related pulmonary embolism: Analysis of 562 consecutive patients from the EPIPHANY study.
• C0271: Incidental Versus Symptomatic Pulmonary Embolism (PE) in Cancer Patients: Clinical Features and Short Term Outcomes of 562 Consecutive Patients from the Epiphany Study
• 227 Predictive serum biomarkers in metastatic colorectal cancer patients treated in the BECOX trial with oxaliplatin-capecitabine (CAPOX) plus bevacizumab (GEMCAD 09-01)
• Outpatient Management of Cancer-Related Pulmonary Embolism: a Propensity Score-Matched Analysis of 803 Patients from the Epiphany Study
• Prognostic Evaluation of a Multicenter Cohort of 484 Patients with Metastatic Gastroesophageal Adenocarcinoma
• Pro-tumor and prothrombotic activities of hepsin in colorectal cancer cells and suppression by venetoclax
• Prognostic Evaluation of Clinically Stable Febrile Neutropenia: Prospective Data from 921 Patients from the Finite Study
• 2261 Comparison of four prognostic tools based on clinical features for metastatic gastric cancer
• First-Line Chemotherapy for Patients with Gastroesophageal Adenocarcinoma in the Community Setting: a Multicenter Cohort of 418 Patients
• Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin: the phase II DUNE trial (GETNE 1601)
• Correlation of hypertension and proteinuria with outcomes in elderly bevacizumab (BEV)-treated patients with metastatic colorectal cancer (mCRC): Analysis of the BECOX and BECA studies.
• Stoicism and its relation with clincal-pathological variables in patients with resected cancer undergoing adjuvant chemotherapy treatment
• Prognostic factors for survival in patients with advanced gastric cancer treated with chemotherapy.
• Everolimus (Eve) Treatment for Advanced G1-G2 Neuroendocrine Tumours (Nets) in the Community Setting: Clinical Benefit Irrespective of Grade or Primary Tumour Site
• Prognostic value of computed tomography in acute pulmonary thromboembolism,Valor pronóstico de la tomografía computarizada en la tromboembolia pulmonar aguda
• Pulmonary embolism in patients with cancer: Foundations of the EPIPHANY study,Embolia pulmonar en el paciente oncológico: bases para el estudio EPIPHANY
• Dysphagia in post-extubation respiratory failure: Potential implications of noninvasive ventilation
• Toxicities and palliative treatment of chemoradiation applied to head and neck tumors,Toxicidades y tratamiento de soporte de la radioquimioterapia aplicados a los tumores de cabeza y cuello
• Aorto-left atrial fistula secondary to infective endocarditis,Fístula aortoauricular izquierda secundaria a endocarditis infecciosa
• Guillain-Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyound anecdotal evidence?
• Endovascular treatment of descending thoracic aortic rupture: Mid- to long-term results in a single-centre registry
• First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
• Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer
• SEOM Clinical Guideline for bone metastases from solid tumours (2016)
• An evolutionary explanation for the perturbation of the dynamics of metastatic tumors induced by surgery and acute inflammation
• Postextubation dysphagia in critically ill trauma patients. Are necessary new screening methods? Some practical comments
• Toxic epidermal necrolysis treated with cyclosporin A,Tratamiento de necrólisis epidermica tóxica con ciclosporina A
• Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer